## Michael Wall

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7086302/publications.pdf

Version: 2024-02-01

130	7,362	39	78
papers	citations	h-index	g-index
135	135	135	3637
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The Incidence of Pseudotumor Cerebri. Archives of Neurology, 1988, 45, 875.	4.9	599
2	Idiopathic Intracranial Hypertension. Neurologic Clinics, 2010, 28, 593-617.	0.8	388
3	Effect of Acetazolamide on Visual Function in Patients With Idiopathic Intracranial Hypertension and Mild Visual Loss. JAMA - Journal of the American Medical Association, 2014, 311, 1641.	3.8	383
4	High- and Low-Risk Profiles for the Development of Multiple Sclerosis Within 10 Years After Optic Neuritis. JAMA Ophthalmology, 2003, 121, 944.	2.6	361
5	The Idiopathic Intracranial Hypertension Treatment Trial. JAMA Neurology, 2014, 71, 693.	4.5	336
6	Profiles of Obesity, Weight Gain, and Quality of Life in Idiopathic Intracranial Hypertension (Pseudotumor Cerebri). American Journal of Ophthalmology, 2007, 143, 635-641.e1.	1.7	240
7	Diagnosis and Grading of Papilledema in Patients With Raised Intracranial Pressure Using Optical Coherence Tomography vs Clinical Expert Assessment Using a Clinical Staging Scale. JAMA Ophthalmology, 2010, 128, 705.	2.6	231
8	Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. American Journal of Ophthalmology, 2004, 137, 77-83.	1.7	219
9	Structure versus Function in Glaucoma: An Application of a Linear Model. , 2007, 48, 3662.		201
10	Prevalence of a Normal C-Reactive Protein with an Elevated Erythrocyte Sedimentation Rate in Biopsy-Proven Giant Cell Arteritis. Ophthalmology, 2006, 113, 1842-1845.	2.5	188
11	Sleep apnea and intracranial hypertension in men. Ophthalmology, 2002, 109, 482-485.	2.5	133
12	The Headache Profile of Idiopathic Intracranial Hypertension. Cephalalgia, 1990, 10, 331-335.	1.8	127
13	Repeatability of Automated Perimetry: A Comparison between Standard Automated Perimetry with Stimulus Size III and V, Matrix, and Motion Perimetry. , 2009, 50, 974.		122
14	The Use of Acetazolamide in Idiopathic Intracranial Hypertension During Pregnancy. American Journal of Ophthalmology, 2005, 139, 855-859.	1.7	121
15	Headache in Idiopathic Intracranial Hypertension: Findings From the Idiopathic Intracranial Hypertension Treatment Trial. Headache, 2017, 57, 1195-1205.	1.8	118
16	Epidemiology and Risk Factors for Idiopathic Intracranial Hypertension. International Ophthalmology Clinics, 2014, 54, 1-11.	0.3	114
17	Neuro-ophthalmic Sarcoidosis: The University of Iowa Experience. Seminars in Ophthalmology, 2008, 23, 157-168.	0.8	107
18	Visual acuity scored by the letter-by-letter or probit methods has lower retest variability than the line assignment method. Eye, 1997, 11, 411-417.	1.1	104

#	Article	IF	CITATIONS
19	Visual Loss in Pseudotumor Cerebri. Archives of Neurology, 1987, 44, 170.	4.9	103
20	Idiopathic Intracranial Hypertension (Pseudotumor Cerebri): Recognition, Treatment, and Ongoing Management. Current Treatment Options in Neurology, 2013, 15, 1-12.	0.7	99
21	A Test of a Linear Model of Glaucomatous Structure–Function Loss Reveals Sources of Variability in Retinal Nerve Fiber and Visual Field Measurements. , 2009, 50, 4254.		98
22	Update on Idiopathic Intracranial Hypertension. Neurologic Clinics, 2017, 35, 45-57.	0.8	93
23	Idiopathic intracranial hypertension (Pseudotumor cerebri). Current Neurology and Neuroscience Reports, 2008, 8, 87-93.	2.0	92
24	Visual Field Defects in Idiopathic Intracranial Hypertension (Pseudotumor Cerebri). American Journal of Ophthalmology, 1983, 96, 654-669.	1.7	89
25	Characteristics of the Normative Database for the Humphrey Matrix Perimeter., 2005, 46, 1540.		89
26	Neurologic Impairment 10 Years After Optic Neuritis. Archives of Neurology, 2004, 61, 1386-1389.	4.9	80
27	Quality of life in idiopathic intracranial hypertension at diagnosis. Neurology, 2015, 84, 2449-2456.	1.5	79
28	Causes and Prognosis of Visual Acuity Loss at the Time of Initial Presentation in Idiopathic Intracranial Hypertension., 2015, 56, 3850.		70
29	The Idiopathic Intracranial Hypertension Treatment Trial. Journal of Neuro-Ophthalmology, 2014, 34, 107-117.	0.4	69
30	Presumed "sulfa allergy―in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality?. American Journal of Ophthalmology, 2004, 138, 114-118.	1.7	67
31	Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial. Journal of Neuro-Ophthalmology, 2016, 36, 13-19.	0.4	65
32	The Effective Dynamic Ranges of Standard Automated Perimetry Sizes III and V and Motion and Matrix Perimetry. JAMA Ophthalmology, 2010, 128, 570.	2.6	62
33	Normal Aging Effects for Frequency Doubling Technology Perimetry. Optometry and Vision Science, 1999, 76, 582-587.	0.6	61
34	Idiopathic Intracranial Hypertension. Archives of Neurology, 1995, 52, 141.	4.9	60
35	The Repeatability of Mean Defect with Size III and Size V Standard Automated Perimetry. , 2013, 54, 1345.		60
36	Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension. Neurology, 2015, 85, 799-805.	1.5	59

#	Article	IF	CITATIONS
37	Long- and Short-term Variability of Automated Perimetry Results in Patients With Optic Neuritis and Healthy Subjects. JAMA Ophthalmology, 1998, 116, 53.	2.6	56
38	Baseline Visual Field Findings in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)., 2014, 55, 3200.		56
39	Manetic Resonance, Imaging in the Evaluation of Optic Nerve Gliomas. Ophthalmology, 1987, 94, 709-717.	2.5	53
40	Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology, 2014, 83, 198-200.	1.5	50
41	Random Dot Motion Perimetry in Patients With Glaucoma and in Normal Subjects. American Journal of Ophthalmology, 1995, 120, 587-596.	1.7	48
42	Threshold Amsler Grid Testing. JAMA Ophthalmology, 1986, 104, 520.	2.6	46
43	Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)., 2016, 57, 805.		44
44	Sensitivity and specificity of frequency doubling perimetry in neuro-ophthalmic disorders: a comparison with conventional automated perimetry. Investigative Ophthalmology and Visual Science, 2002, 43, 1277-83.	3.3	44
45	A History of Perimetry and Visual Field Testing. Optometry and Vision Science, 2011, 88, E8-E15.	0.6	42
46	Size Threshold Perimetry Performs as Well as Conventional Automated Perimetry With Stimulus Sizes III, V, and VI for Glaucomatous Loss., 2013, 54, 3975.		41
47	CSF pressure, papilledema grade, and response to acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial. Journal of Neurology, 2015, 262, 2271-2274.	1.8	40
48	Prognosis of ischemic internuclear ophthalmoplegia. Ophthalmology, 2002, 109, 1676-1678.	2.5	39
49	Quality of life at 6 months in the Idiopathic Intracranial Hypertension Treatment Trial. Neurology, 2016, 87, 1871-1877.	1.5	36
50	Imaging and Perimetry Society Standards and Guidelines. Optometry and Vision Science, 2011, 88, 4-7.	0.6	35
51	Motion Perimetry Identifies Nerve Fiber Bundlelike Defects in Ocular Hypertension. JAMA Ophthalmology, 1997, 115, 26.	2.6	34
52	The Diagnostic Yield of the Evaluation for Isolated Unexplained Optic Atrophy. Ophthalmology, 2005, 112, 757-759.	2.5	34
53	Automated perimetry in amblyopia: a generalized depression. American Journal of Ophthalmology, 1999, 127, 312-321.	1.7	33
54	Papilledema as the Presenting Manifestation of Spinal Schwannoma. Journal of Neuro-Ophthalmology, 2002, 22, 199-203.	0.4	33

#	Article	IF	CITATIONS
55	Papilledema: Are We Any Nearer to a Consensus on Pathogenesis and Treatment?. Current Neurology and Neuroscience Reports, 2012, 12, 334-339.	2.0	33
56	Contrast Sensitivity Testing in Pseudotumor Cerebri. Ophthalmology, 1986, 93, 4-7.	2.5	32
57	The Effect of Attention on Conventional Automated Perimetry and Luminance Size Threshold Perimetry. , 2004, 45, 342.		32
58	Idiopathic intracranial hypertension in men and the relationship to sleep apnea. Neurology, 2009, 72, 300-301.	1.5	32
59	Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial. Journal of Neuro-Ophthalmology, 2016, 36, 6-12.	0.4	32
60	Threshold Amsler Grid Testing in Maculopathies. Ophthalmology, 1987, 94, 1126-1133.	2.5	29
61	Subretinal Neovascular Membrane in Idiopathic Intracranial Hypertension. American Journal of Ophthalmology, 2006, 141, 573-574.	1.7	29
62	Intracranial Hypertension in Systemic Lupus Erythematosus. Seminars in Ophthalmology, 2008, 23, 127-133.	0.8	29
63	Role of vitamin A metabolism in IIH: Results from the idiopathic intracranial hypertension treatment trial. Journal of the Neurological Sciences, 2017, 372, 78-84.	0.3	29
64	Idiopathic intracranial hypertension (pseudotumor cerebri). Current Neurology and Neuroscience Reports, 2008, 8, 87-93.	2.0	29
65	Perimetric Evaluation of Saccadic Latency, Saccadic Accuracy, and Visual Threshold for Peripheral Visual Stimuli in Young Compared With Older Adults. , 2013, 54, 5778.		28
66	The Effective Dynamic Ranges for Glaucomatous Visual Field Progression With Standard Automated Perimetry and Stimulus Sizes III and V. , 2018, 59, 439.		28
67	Small Capsular Hemorrhages. Archives of Neurology, 1984, 41, 1255.	4.9	27
68	Idiopathic Intracranial Hypertension and the Idiopathic Intracranial Hypertension Treatment Trial. Journal of Neuro-Ophthalmology, 2013, 33, 1-3.	0.4	25
69	Refinement of Pointwise Linear Regression Criteria for Determining Glaucoma Progression. , 2013, 54, 6234.		24
70	Photographic Reading Center of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT): Methods and Baseline Results., 2015, 56, 3292.		24
71	Total Deviation Probability Plots for Stimulus Size V Perimetry. JAMA Ophthalmology, 2008, 126, 473.	2.6	23
72	The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes From MonthsÂ6–12. American Journal of Ophthalmology, 2017, 176, 102-107.	1.7	23

#	Article	IF	CITATIONS
73	Idiopathic Intracranial Hypertension. Seminars in Ophthalmology, 1995, 10, 251-259.	0.8	22
74	Optic disc haemorrhages at baseline as a risk factor for poor outcome in the Idiopathic Intracranial Hypertension Treatment Trial. British Journal of Ophthalmology, 2017, 101, 1256-1260.	2.1	22
75	The relationship of visual threshold and reaction time to visual field eccentricity with conventional automated perimetry. Vision Research, 2002, 42, 781-787.	0.7	21
76	Pattern of axonal loss in longstanding papilledema due to idiopathic intracranial hypertension. Current Eye Research, 1995, 14, 173-180.	0.7	19
77	What???s New in Perimetry. Journal of Neuro-Ophthalmology, 2004, 24, 46-55.	0.4	18
78	A Comparison of False-negative Responses for Full Threshold and SITA Standard Perimetry in Glaucoma Patients and Normal Observers. Journal of Glaucoma, 2014, 23, 288-292.	0.8	18
79	Threshold Static Automated Perimetry of the Full Visual Field in Idiopathic Intracranial Hypertension. , 2019, 60, 1898.		18
80	Perimetry, Retinal Nerve Fiber Layer Thickness and Papilledema Grade After Cerebrospinal Fluid Shunting in Patients With Idiopathic Intracranial Hypertension. Journal of Neuro-Ophthalmology, 2015, 35, 22-25.	0.4	17
81	Is Management of Central Retinal Artery Occlusion the Next Frontier in Cerebrovascular Diseases?. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 2781-2791.	0.7	17
82	Sensitivity and Specificity of the Humphrey Matrix to Detect Homonymous Hemianopias., 2008, 49, 924.		15
83	Genetic Survey of Adult-Onset Idiopathic Intracranial Hypertension. Journal of Neuro-Ophthalmology, 2019, 39, 50-55.	0.4	15
84	A comparison of three clinical methods of spatial contrast-sensitivity testing in normal subjects. Graefe's Archive for Clinical and Experimental Ophthalmology, 1990, 228, 24-27.	1.0	13
85	Tadalafil Associated with Typical Migraine Aura without Headache. Cephalalgia, 2006, 26, 1344-1346.	1.8	13
86	Idiopathic Intracranial Hypertension. Ophthalmology, 2007, 114, 617.e1-617.e2.	2.5	13
87	Humphrey Matrix Perimetry in Optic Nerve and Chiasmal Disorders: Comparison with Humphrey SITA Standard 24-2., 2008, 49, 917.		13
88	Random Dot Motion Stimuli Are More Sensitive than Light Stimuli for Detection of Visual Field Loss in Ocular Hypertension Patients. Optometry and Vision Science, 1999, 76, 550-557.	0.6	12
89	Visual Field of High-Pass Resolution Perimetry in Normal Subjects. Journal of Glaucoma, 2004, 13, 15-21.	0.8	11
90	A Comparison of Catch Trial Methods Used in Standard Automated Perimetry in Glaucoma Patients. Journal of Glaucoma, 2008, 17, 626-630.	0.8	11

#	Article	IF	CITATIONS
91	Rapid confrontation screening for peripheral visual field defects and extinction. Australasian journal of optometry, The, 2009, 92, 45-48.	0.6	11
92	Validation of the UNC OCT Index for the Diagnosis of Early Glaucoma. Translational Vision Science and Technology, 2018, 7, 16.	1.1	11
93	Optic disk edema with cotton-wool spots. Survey of Ophthalmology, 1995, 39, 502-508.	1.7	10
94	Use of a Continuous Probability Scale to Display Visual Field Damage. JAMA Ophthalmology, 2009, 127, 749.	2.6	10
95	The Importance of Visual Field Testing in Idiopathic Intracranial Hypertension. CONTINUUM Lifelong Learning in Neurology, 2014, 20, 1067-1074.	0.4	10
96	Temporal Wedge Defects in Glaucoma: Structure/Function Correlation With Threshold Automated Perimetry of the Full Visual Field. Journal of Glaucoma, 2020, 29, 191-197.	0.8	10
97	To the editor: Comment on Mallol et al Pediatric Pulmonology, 2001, 32, 263-263.	1.0	9
98	Variability of Rarebit and Standard Perimetry Sizes I and III in Normals. Optometry and Vision Science, 2011, 88, 635-639.	0.6	9
99	Motion perimetry in anisometropic amblyopia: Elevated size thresholds extend into the midperiphery. Journal of AAPOS, 1998, 2, 94-101.	0.2	8
100	Data obtained with an open-source static automated perimetry test of the full visual field in healthy adults. Data in Brief, 2018, 21, 75-82.	0.5	8
101	A 6â€month telephoneâ€based weight loss intervention in overweight and obese subjects with idiopathic intracranial hypertension. Obesity Science and Practice, 2016, 2, 95-103.	1.0	7
102	Unsupervised Machine Learning Identifies Quantifiable Patterns of Visual Field Loss in Idiopathic Intracranial Hypertension. Translational Vision Science and Technology, 2021, 10, 37.	1.1	7
103	CT findings in acute optic neuritis. Computerized Radiology: Official Journal of the Computerized Tomography Society, 1984, 8, 91-94.	0.1	5
104	Neurosarcoidosis involving optic nerves and leptomeninges: computed tomography findings. The Journal of Computed Tomography, 1986, 10, 129-133.	0.1	5
105	Optic atrophy. Survey of Ophthalmology, 1991, 36, 51-58.	1.7	5
106	Letter From the DSMC Regarding a Clinical Trial of Lutein in Patients With Retinitis Pigmentosa. JAMA Ophthalmology, 2011, 129, 664.	2.6	5
107	Integrating independent spatioâ€ŧemporal replications to assess population trends in disease spread. Statistics in Medicine, 2016, 35, 5210-5221.	0.8	5
108	Indomethacin-sensitive monocyte killing defect in a child with disseminated atypical mycobacterial disease. Journal of Clinical Immunology, 1991, 11, 357-362.	2.0	4

#	Article	IF	CITATIONS
109	SITA-Standard perimetry has better performance than FDT2 matrix perimetry for detecting glaucomatous progression. British Journal of Ophthalmology, 2018, 102, 1396-1401.	2.1	4
110	Threshold Automated Perimetry of the Full Visual Field in Patients With Glaucoma With Mild Visual Loss. Journal of Glaucoma, 2019, 28, 997-1005.	0.8	4
111	The Visual Field. , 2011, , 655-676.		4
112	Benefit of Stimulus Size V Perimetry for Patients With a Dense Central Scotoma From Leber's Hereditary Optic Neuropathy. Translational Vision Science and Technology, 2021, 10, 31.	1.1	4
113	Archetypal Analysis Reveals Quantifiable Patterns of Visual Field Loss in Optic Neuritis. Translational Vision Science and Technology, 2022, 11, 27.	1.1	4
114	Unsupervised Machine Learning Shows Change in Visual Field Loss in the Idiopathic Intracranial Hypertension Treatment Trial. Ophthalmology, 2022, 129, 903-911.	2.5	4
115	Interferon Treatment of SRNV. Ophthalmology, 1994, 101, 624-625.	2.5	3
116	The Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC). Journal of Neuro-Ophthalmology, 2009, 29, 259-261.	0.4	3
117	Idiopathic Intracranial Hypertension—Reply. JAMA - Journal of the American Medical Association, 2014, 312, 1060.	3.8	3
118	Reader response: Visual discrimination training improves Humphrey perimetry in chronic cortically induced blindness. Neurology, 2018, 90, 436-437.	1.5	3
119	Morphology and Repeatability of Automated Perimetry using Stimulus Sizes III, V and VI. Medical Research Archives, 2020, 8, .	0.1	3
120	The Open Perimetry Initiative: A framework for cross-platform development for the new generation of portable perimeters. Journal of Vision, 2022, 22, 1.	0.1	2
121	Nerve Sheath Decompression in Patients with Functioning Shunts. Ophthalmology, 1992, 99, 480.	2.5	1
122	Neuro-ophthalmic manifestations of hemangiopericytoma. Seminars in Ophthalmology, 2004, 19, 95-100.	0.8	1
123	Cup-to-Disc Ratio in Patients With Idiopathic Intracranial Hypertension Is Smaller Than in Normal Subjects?. Journal of Neuro-Ophthalmology, 2011, 31, 95-96.	0.4	1
124	Bilateral jugular paragangliomas. Neurology, 2014, 82, 732-733.	1.5	1
125	Perimetry and visual field defects. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 178, 51-77.	1.0	1
126	Idiopathic intracranial hypertension (pseudotumor cerebri). Insight, 2008, 33, 18-25; quiz 26-7.	0.1	1

#	Article	IF	CITATIONS
127	Luminance contrast and colour contrast related errors in pseudoisochromatic plate identification. Eye, 1997, 11, 713-716.	1.1	O
128	Treating Idiopathic Intracranial Hypertension—Reply. JAMA Neurology, 2014, 71, 1327.	4.5	0
129	Medical Treatment of Idiopathic Intracranial Hypertension (IIH)., 2019,, 61-66.		0
130	Examination of the Ten Degrees of Visual field Surrounding Fixation. , 1989, , 94-111.		0